KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Depreciation & Amortization (CF) (2018 - 2025)

Moderna (MRNA) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $67.0 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 11.67% to $67.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $215.0 million through Dec 2025, up 13.76% year-over-year, with the annual reading at $215.0 million for FY2025, 13.76% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $67.0 million at Moderna, up from $52.0 million in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $249.0 million in Q3 2023, with the low at $15.0 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $80.2 million, with a median of $69.5 million recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) surged 1014.29% in 2021, then plummeted 79.12% in 2024.
  • Over 5 years, Depreciation & Amortization (CF) stood at $78.0 million in 2021, then grew by 2.56% to $80.0 million in 2022, then skyrocketed by 152.5% to $202.0 million in 2023, then tumbled by 70.3% to $60.0 million in 2024, then increased by 11.67% to $67.0 million in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $67.0 million, $52.0 million, and $57.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.